Browse by author
Lookup NU author(s): Dr Calum Hamilton, Professor John O'Brien, Dr Rory Durcan, Dr Sarah Lawley, Nicola Barnett, Dr Gemma Roberts, Dr Michael FirbankORCiD, Professor John-Paul TaylorORCiD, Professor Alan ThomasORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Background Blood biomarkers of Alzheimer’s disease (AD) may allow for the early detection of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co-pathology in MCI with Lewy bodies (MCI-LB). However not all cases of MCI-LB will feature AD pathology. Disease-general biomarkers of neurodegeneration, such as glial fibrillary acidic protein (GFAP) or neurofilament light (NfL), may therefore provide a useful supplement to AD biomarkers. We aimed to compare the relative utility of plasma Aβ42/40, p-tau181, GFAP and NfL in differentiating MCI-AD and MCI-LB from cognitively healthy older adults, and from one another. Methods Plasma samples were analysed for 172 participants (31 healthy controls, 48 MCI-AD, 28 possible MCI-LB and 65 probable MCI-LB) at baseline, and a subset (n = 55) who provided repeated samples after ≥1 year. Samples were analysed with a Simoa 4-plex assay for Aβ42, Aβ40, GFAP and NfL, and incorporated previously-collected p-tau181 from this same cohort. Results Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower Aβ42/40 (p = 0.06). GFAP and p-tau181 were higher in MCI-AD than MCI-LB. GFAP discriminated all MCI subgroups, from controls (AUC of 0.75), but no plasma-based marker effectively differentiated MCI-AD from MCI-LB. NfL correlated with disease severity and increased with MCI progression over time (p = 0.011). Conclusion Markers of AD and astrocytosis/neurodegeneration are elevated in MCI-LB. GFAP offered similar utility to p-tau181 in distinguishing MCI overall, and its subgroups, from healthy controls.
Author(s): Hamilton CA, O'Brien JT, Heslegrave A, Laban R, Donaghy PC, Durcan R, Lawley S, Barnett NA, Roberts G, Firbank M, Taylor JP, Zetterberg H, Thomas AJ
Publication type: Article
Publication status: Published
Journal: Psychological Medicine
Year: 2023
Volume: 53
Issue: 16
Pages: 7865-7873
Print publication date: 01/12/2023
Online publication date: 25/07/2023
Acceptance date: 23/06/2023
Date deposited: 26/06/2023
ISSN (print): 0033-2917
ISSN (electronic): 1469-8978
Publisher: Cambridge University Press
URL: https://doi.org/10.1017/S0033291723001952
DOI: 10.1017/S0033291723001952
Data Access Statement: Data from these studies are available upon request through Dementias platform UK.
Altmetrics provided by Altmetric
